Rx only · Tablet, Film Coated · Oral

Valsartan

20 ACTIVE SUPPLIERS — US

openFDA · updated weekly

US73 NDCs
20 active makers

UKComing
soon

CAComing
soon

AUComing
soon

EUComing
soon

ATCC09CA03

RxCUI (US)69749

US makers20 labelers

Packages188

DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 38 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.118

Latest avg · Jul 22, 2026

-15%

Since Dec 17, 2025

Active US suppliers

33%

Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

127K

Rx · 2026 Q1

6.7M

Units dispensed

-18%

Rx vs. year ago

Quarters · since 2025 Q1

Who makes it20 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

Labeler	Type	Packages	Status
Camber Pharmaceuticals, Inc.	unknown	40	SUPPLYING
Dr.Reddy's laboratories Limited	unknown	22	SUPPLYING
Bryant Ranch Prepack	repackager	18	SUPPLYING
Laurus Labs Limited	unknown	15	SUPPLYING
Unichem Pharmaceuticals (USA), Inc.	unknown	12	SUPPLYING
OHM LABORATORIES INC	unknown	12	SUPPLYING
Ascend Laboratories, LLC	unknown	12	SUPPLYING
A-S Medication Solutions	unknown	8	SUPPLYING
Aurobindo Pharma Limited	unknown	8	SUPPLYING
Macleods Pharmaceuticals Limited	unknown	8	SUPPLYING
Northwind Health Company, LLC	unknown	5	SUPPLYING
Proficient Rx LP	unknown	5	SUPPLYING
Zydus Lifesciences Limited	unknown	4	SUPPLYING
AvPAK	unknown	4	SUPPLYING
Mylan Pharmaceuticals Inc.	unknown	4	SUPPLYING

+ 5 more labelers

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

Nov 19, 2025
RESOLVEDShortage resolved: Valsartan Tablet (Mylan Pharmaceuticals Inc., a Viatris Company)
Valsartan Tablet — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Cardiovascular.
Nov 19, 2025
SHORTAGEDrug shortage: Valsartan Tablet (Mylan Pharmaceuticals Inc., a Viatris Company)
Valsartan Tablet — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Cardiovascular.
Dec 31, 2018
RECALLRecall (Class II): Valsartan Tablets USP 160 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC…
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.
Dec 31, 2018
RECALLRecall (Class II): Valsartan Tablets USP 320 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- ND…
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.
Dec 31, 2018
RECALLRecall (Class II): Valsartan Tablets USP 40 mg, 30 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC…
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.
Dec 31, 2018
RECALLRecall (Class II): Valsartan tablets USP 320 mg, 90-count bottles, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810…
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to 25 distributors and Retail Chains who may have further distributed the product throughout th…
Dec 31, 2018
RECALLRecall (Class II): Valsartan Tablets USP 80 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC …
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.
Dec 4, 2018
RECALLRecall (Class II): Valsartan Tablets, USP 80 mg, 90-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., …
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
Dec 4, 2018
RECALLRecall (Class II): Valsartan Tablets, USP 40 mg, 30-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., …
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
Dec 4, 2018
RECALLRecall (Class II): Valsartan Tablets, USP 320 mg, 90-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc.,…
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
Dec 4, 2018
RECALLRecall (Class II): Valsartan Tablets, USP 160 mg, 90-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc.,…
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
Nov 20, 2018
RECALLRecall (Class II): Valsartan Tablets, USP, 160 mg, 90-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc.,…
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
Nov 20, 2018
RECALLRecall (Class II): Valsartan Tablets, USP, 80 mg, 90-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc.,…
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
Nov 20, 2018
RECALLRecall (Class II): Valsartan Tablets, USP, 40 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., …
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
Nov 20, 2018
RECALLRecall (Class II): Valsartan Tablets, USP, 320 mg, 90-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc.,…
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
Aug 8, 2018
RECALLRecall (Class II): Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only Manufactured for: Camber Pharmaceutic…
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide
Aug 8, 2018
RECALLRecall (Class II): Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 320 mg, 90 tablets, Rx Only Manufactured for: Camber Pharmaceuti…
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide
Aug 8, 2018
RECALLRecall (Class II): Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 40 mg, 30 Tablets Rx Only Manufactured for: Camber Pharmaceutica…
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide
Aug 8, 2018
RECALLRecall (Class II): Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 80 mg, 90 count bottles, Rx Only Manufactured for: Camber Pharma…
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide